Initiator aims to develop safe and efficacious therapeutics. Pudafensine (API code: IP2015) is being developed in two clinical indications: i) Erectile dysfunction (IPED2015 program) and ii) Neuropathic pain—Vulvodynia (IPVU2025 program).
The drug candidates belong to the drug class known as monoamine reuptake inhibitors and is based on compounds modulating monoamine neurotransmitters e.g., dopamine, noradrenaline, and serotonin. Modulation and regulation of monoamines are indeed validated and efficacious therapy for a broad range of medical conditions. The monoaminergic system plays a pivotal role in many important physiological functions, e.g., mood, pain, arousal, sexual function, and might be used to treat depression, attention deficit hyperactive disorder (ADHD), narcolepsy, and anxiety. The major challenge with targeting the monoaminergic system is ensuring that the modulation is a safe, without the adverse effects (AEs) known from previously and currently marketed monoamine modulation drugs, e.g., liver tox and sexual dysfunction.
Initiator Pharma has a pipeline of clearly differentiated monoamine modulation drug candidates with attractive safety profiles.
*IP2015 API